# Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

> **NCT02765256** · PHASE2 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 8 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Fluconazole
- **DRUG:** Vancomycin
- **DRUG:** Neomycin
- **DRUG:** Ciprofloxacin
- **DRUG:** Polyethylene Glycol 3350
- **DRUG:** Promethazine
- **DRUG:** Fluconazole placebo

## Key facts

- **NCT ID:** NCT02765256
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02765256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02765256, "Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02765256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*